Category: Broker Research


BHFC is the flagship company of Kalyani Group. It is one of the largest commercial forging companies in the world in terms of capacity and revenue, with presence in auto as well as non-auto component sectors with wide domain knowledge in design and engineering.
May 27, 2019, 1:21 p.m.
Publisher: edelweiss.in

At the current market price, the bank’s core banking business (after adjusting the value of subsidiaries) is trading at 1.6x FY2021E ABV.
May 25, 2019, 2:01 p.m.
Publisher: angelbroking.com

We expect STFC’s AUM to grow at CAGR of 16% over FY2019-21E primarily owing to (1) post election government to increase spending on infra project (macro recovery), and (2) pre-buying of CV before the BS VI will also improve the pricing of older vehicles. We expect STFC to report RoA/RoE to 2.7%/17.6%.
May 25, 2019, 2:01 p.m.
Publisher: angelbroking.com

The stock currently trades at 22.5x FY19 EPS of Rs 11.64 and 18.7x FY20e EPS of Rs 13.97. Setting up agglomeration unit in India is aimed at enhanced value addition for agglomerated products generally command 4-5% higher margins compared to spray dried products.
May 21, 2019, 4:16 p.m.


We feel investors could buy the stock at the CMP and add on dips to Rs ~221-225 band (14.0x CY20E EPS) for sequential targets of Rs 287 (18.0x CY20E EPS) and Rs 303 (19.0x CY20E EPS). At the CMP of Rs 250 the stock trades at 15.7x CY20E EPS.
May 20, 2019, 5:19 p.m.
Author : HDFC Sec | Publisher: indianotes.com

Tata Steel Limited and Thyssenkrupp AG of Germany had signed definitive agreements in June 2018 to combine their business in Europe to create a 50:50 joint venture company which could have become second largest steel company in the European continent.
May 20, 2019, 1 p.m.
Publisher: karvyonline.com

Despite top line growth of 16%, margins were impacted on account of higher operating costs and increasing competition.
May 20, 2019, 12:59 p.m.

PHNX’s revenue grew 66%/64% YoY/QoQ to Rs. 7233 Mn.
May 20, 2019, 12:59 p.m.
Publisher: karvyonline.com

Strong demand outlook in US and stable demand in Europe/South America/Asia, aided by quality operations and sound B/S sets firm outlook for Novelis.
May 9, 2019, 11:42 a.m.
Publisher: plindia.com

With three European and two US approvals in place, Biocon is in the first row when the monetisation cycle of biosimilars began. Looking ahead, we expect the biosimilars will penetrate faster in the US healthcare industry with rising interest to adopt biosimilars.
May 7, 2019, 11:47 a.m.
Publisher: ashikagroup.com